Law.com Subscribers SAVE 30%
Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.
Drug & Device News
Side-Effect of Anti-Baldness Drug: Better Prostate Health
A study of men who took baldness-treatment drug finasteride for many years shows that the medication has a significant side benefit: It appears to reduce by 30% the chance of a man's developing' prostate cancer. Thompson, Ian M. Jr., et. al, “Long-Term Survival of Participants in the Prostate Cancer Prevention Trial,” N Engl J Med 2013; 369:603-610 Aug. 15, 2013DOI: 10.1056/NEJMoa1215932. The connection between finasteride and prostate health is not completely unexpected, as men have been prescribed the drug for years for reducing the size of enlarged prostate glands, athough this off-label use has not been approved by the FDA. The results of this latest study found that 14.9% of men who did not take finasteride developed prostate cancer, while only 10.5% of the group who took the drug were so afflicted. This suggests that men may want to take the medication as a preventive measure, particularly if they are at a higher risk for the cancer, even though the kind of prostate cancer apparently prevented by finasteride use is the low-grade type that is not likely to lead to death. Preventing this type is worthwhile because the damage done to men who are treated for prostate cancer that is not likely to shorten their lives often leaves them impotent and/or incontinent.
This premium content is locked for LJN Newsletters subscribers only
ENJOY UNLIMITED ACCESS TO THE SINGLE SOURCE OF OBJECTIVE LEGAL ANALYSIS, PRACTICAL INSIGHTS, AND NEWS IN ENTERTAINMENT LAW.
- Stay current on the latest information, rulings, regulations, and trends
- Includes practical, must-have information on copyrights, royalties, AI, and more
- Tap into expert guidance from top entertainment lawyers and experts
Already a have an account? Sign In Now Log In Now
For enterprise-wide or corporate acess, please contact Customer Service at [email protected] or 877-256-2473
The DOJ's Corporate Enforcement Policy: One Year Later
The DOJ's Criminal Division issued three declinations since the issuance of the revised CEP a year ago. Review of these cases gives insight into DOJ's implementation of the new policy in practice.
The DOJ's New Parameters for Evaluating Corporate Compliance Programs
The parameters set forth in the DOJ's memorandum have implications not only for the government's evaluation of compliance programs in the context of criminal charging decisions, but also for how defense counsel structure their conference-room advocacy seeking declinations or lesser sanctions in both criminal and civil investigations.
Use of Deferred Prosecution Agreements In White Collar Investigations
This article discusses the practical and policy reasons for the use of DPAs and NPAs in white-collar criminal investigations, and considers the NDAA's new reporting provision and its relationship with other efforts to enhance transparency in DOJ decision-making.
Bankruptcy Sales: Finding a Diamond In the Rough
There is no efficient market for the sale of bankruptcy assets. Inefficient markets yield a transactional drag, potentially dampening the ability of debtors and trustees to maximize value for creditors. This article identifies ways in which investors may more easily discover bankruptcy asset sales.
A Lawyer's System for Active Reading
Active reading comprises many daily tasks lawyers engage in, including highlighting, annotating, note taking, comparing and searching texts. It demands more than flipping or turning pages.